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Abstract 
Purpose: To evaluate the protective effects of Cuminum cyminum Linn (Apiaceae, CCY) against 1-
methyl-4 phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP)-induced oxidative stress and behavioral 
impairments in mouse model of Parkinson’s disease (PD). 
Methods: MPTP-intoxicated mice model of PD was used for evaluating the effect of CCY extract on 
behavioral deficits through rota rod, passive avoidance and open field tasks. The effect of CCY extract 
on oxidative stress levels were assessed by estimating enzyme status, including superoxide dismutase 
(SOD), catalase (CAT) and lipid peroxidation(LPO) in brain tissues of MPTP-induced mice.  
Results: MPTP (25 mg/kg, i.p.)-treated mice resulted in a significant (p < 0.001) behavioral deficit in 
locomotor behavior (from 56.24 ± 1.21 to 27.64 ± 0.94) and cognitive functions (from 298 ± 3.68 s to 
207.28 ± 4.12 s) compared with their respective control groups. Administration of CCY extract (100, 200 
and 300 mg/kg, p.o.) for three weeks significantly and dose-dependently improved (p < 0.001 at 300 
mg/kg) locomotor and cognitive deficits in MPTP-treated mice. CCY treatment also significantly (p < 
0.001 at 300 mg/kg) inhibited MPTP-induced decrease in antioxidant enzyme levels (superoxide 
dismutase and catalase) and lipid peroxides in mice brain tissues. 
Conclusion: CCY extract exhibits strong protection against MPTP-induced behavioral deficit through 
enhancement of antioxidant defense mechanisms. Therefore, CCY may be developed as a therapeutic 
strategy in the treatment of neurodegeneration seen in PD. 
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Parkinson's disease (PD) is a progressive 
neurodegenerative disease characterized by a 
loss of dopaminergic neurons in the substantia 
nigra (SN) region of the brain [1]. Although the 
etiology of PD remains unknown, generation of 
reactive oxygen species (ROS) caused by 
oxidative stress together with reduced 
antioxidant defense system in nigrostriatal 
dopaminergic pathway is widely considered as 
one of the major cause of neuronal death [2]. 
Currently available drugs do not halt or slow 
down the progressive neurodegeneration seen in 
PD. These drugs also produce deleterious side-
effects on long term usage. Therefore, alternative 
therapy using natural herbs having 
neuroprotective effects might be necessary in PD 
treatment [3]. 
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Cuminum cyminum Linn (C. cyminum) 
Apiaceaeis is an annual herb widely used as a 
traditional medicine for the treatment of several 
disorders, such as toothaches, dyspepsia, 
diarrhea, epilepsy and jaundice [4].  
Pharmacologically, C. cyminum has been 
reported to possess anti-diabetic, anti-bacterial, 
hepatoprotective, neuroprotective, anti-epileptic, 
hypolipidemic, anti-stress anti-oxidant and 
memory - enhancing properties [5-7]. Recently, 
C. cyminum was also reported to exhibit potent 
immunomodulatory, nephroprotective, anti-stress 
and memory enhancing properties [8-10]. But so 
far their protective effect in neurodegenerative 
disorders such as PD has not been studied. 
 
The neurotoxin, 1-Methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP), is well studied for its 
ability to induce oxidative damage and 
mitochondrial dysfunction in the nigrostriatal 
dopaminergic system in animal models, 
resembling the idiopathic PD in humans [11]. 
MPTP-induction has been well reported for the 
development of cognitive and behavioral deficits 
in both non-human primates and mice models 
[12,13]. Therefore, MPTP-induced neurotoxicity 
in mice is considered as the most useful 
functional model of Parkinsonism [13].  
 
In the present study, the protective effect of C. 
cyminum against MPTP-induced behavioral 
deficits in mouse model of PD was investigated. 
In addition the effect of CCY on the antioxidant 
enzyme status in MPTP-induced mouse brain 
tissues was also evaluated to correlate its 




Chemicals and reagents 
 
MPTP hydrochloride and thiobarbituric acid were 
purchased from Sigma Chemical Co. USA. All 
other chemicals used were of analytical grade. 
Stock solutions of all chemicals were prepared in 
distilled water and the dilutions were made fresh 
on the day of the experiment. 
 
Preparation of extract 
 
Dried fruit of C. cyminum procured in the month 
of August 2008 were obtained from herbal 
market, Vijayawada, India. The fruit was 
authenticated by Dr. K.N. Vidyadar, a Botanist at 
VJ’s College of Pharmacy and Research 
Institute, Andhra University, Rajahmundry, India 
and a voucher specimen (CCY-RJY/08) was 
deposited in Pharmacognosy department of the 
same institute. The fruit (1 kg) was powdered in a 
conventional mixer and grinder and extracted 
with boiling water (5 L) for 30 min in a Soxhlet 
apparatus (Borosil Glass Works Ltd, Mumbai, 
India). The filtrate was evaporated under vacuum 
below 70 °C in a rotary vacuum evaporator 
(Buchi R-210, Mumbai, India) to give a final yield 
of 8.33 %. The obtained C. cyminum extract 
named as CCY here after was dissolved in sterile 
distilled water, filtered on 0.22 µm filters and 




Adult male Swiss albino mice weighing between 
20-25 g were obtained from the Animal House of 
National Institute of Nutrition, Hyderabad, India. 
The animals were housed in an air-conditioned 
animal room at 23 ± 2 oC with 12/12 h light/dark 
photoperiod, and given free access to food 
(Nutravet, Hyderabad) and water ad libitum.  
 
The animals were kept for seven days in 
laboratory for habituation. All animal experiments 
were performed under the guidelines of 
Principles of Laboratory Animal Care (NIH 
publication No. 85-23, revised 1985) [14] and the 
Institutional Animal Care and Use Committee, 
Vishnu Institute of Pharmaceutical Education and 





The mice were divided into five groups (n = 15), 
i.e., vehicle, MPTP (25 mg/kg), MPTP + CCY 
100 mg/kg, MPTP + CCY 200 mg/kg and MPTP 
+ ITE 300 mg/kg. MPTP 25 mg/kg (i.p.) was 
administered along with probenecid 250 mg/kg 
(i.p.) for five consecutive days to induce chronic 
Parkinsonian symptoms in mice as described 
previously [15]. Different doses of CCY (100, 200 
and 300 mg/kg) were prepared freshly by 
dissolving in distilled water and administered on 
day 1 (1 h prior to MPTP administration) and 
continued up to 21 days through oral gavage 
(p.o.).   
 
Locomotor behavioral paradigm was evaluated 
during the course of MPTP administration (Day 
5) and also at the last phase of the study (Day 
20). Cognitive paradigm using passive avoidance 
test was evaluated on day 20 (acquisition) and 
day 21 (retention). Open field test were 
evaluated on day 21. At the end of the study 
mice were sacrificed and their brains were 
isolated by cardiac perfusion. The protocol for 
perfusion and tissue processing was performed 
as described previously [16]. On day 22, all the 
brain tissues were rinsed in ice-cold isotonic 
saline, homogenized with 1 mL of ice-cold 0.1 M 
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phosphate buffer saline (pH 7.4) and centrifuged 
at -4 °C for 15 min. aliquots of homogenates 
were used for estimation of superoxide 
dismutase (SOD), catalase (CAT) and lipid 




In rotarod test (ROTA-ROD for mice 7650 by 
UGO Basile, Varese, Italy), the beam revolves 
around its longitudinal axis and the animal walks 
or runs forward in synchrony. After adaptation for 
5 min, the mice were placed on a horizontal 
plastic rod rotating at a speed of 10 rpm for a 
maximum of 10 min. The period (s) that each 
mouse was able to maintain its balance walking 
on the top of the rod was measured. 
 
Passive avoidance test 
 
A step through type passive avoidance test 
apparatus (GEMINI, Model PACS-30, San Diego 
instruments Int., USA) was used to evaluate the 
effects of CCY extract on learning and memory 
as described previously [17]. The shuttle box is 
divided into two chambers of equal size (23.5 cm 
× 15.5 cm × 15.5 cm) separated by a guillotine 
door. Mice were placed initially in the light 
chamber with the door open. They displayed 
exploratory behavior, and then entered the dark 
compartment. Upon entering the dark 
compartment, the door closed automatically. 
Training was repeated until the mouse entered 
the dark compartment within 20 s (training trial). 
Twenty four hours after the training trial, the 
mouse was placed in the illuminated chamber. 
When the mice entered the dark chamber, 
electric foot shock (1 mA) was delivered for 3 s 
through the grid floor and the door was closed 
automatically (acquisition trial). The mouse was 
again placed in the dark chamber, 24 h after the 
acquisition trial and the latency time to enter the 
dark chamber was measured for 300 s (retention 
trial). If the mice did not enter the dark chamber 
within the cutoff time (300 s), it was assigned a 




Open-field consisted of a square arena of 40 cm 
× 40 cm and a wall 35 cm high. The square 
arena was divided into 16 sub-squares. The test 
was initiated by placing the mouse at the center 
of the arena. The behavior of the mouse was 
then observed for 5 min. After each test, the 
apparatus was thoroughly cleaned with cotton 
pad wetted with 70 % ethanol. The number of 
line crossings (crossing the square boundaries 
with both forepaws), rearing (standing on its hind 
legs), grooming (rubbing the body with paws or 
mouth and rubbing the head with paws) and 
duration of immobility were measured as 




The ability to scavenge the superoxide radicals in 
the brain homogenate generated by auto-
oxidation of pyrogallol in the alkaline medium 
was measured. Each 3mL reaction mixture 
contained 2.8 mL of potassium phosphate buffer 
(0.1 M, pH 7.4), 0.1mL tissue homogenate and 
0.1 mL pyrogallol solution (2.6 mM in 10 
mMHCl). Increase in the absorbance at 325 nm 
was recorded spectrophotometrically for a period 
of 5 min at 30 s interval (UV- 1601, Shimadzu). 
One unit of SOD is defined as the amount of 
enzyme required to cause 50 % inhibition of 





CAT activity was assessed by the method 
described previously [16]. Briefly, catalase 
activity is measured by the decomposition of 
hydrogen peroxide (H2O2) or by liberation of 
oxygen (O2). The decrease in the absorbance by 
H2O2 as a function of time is used to follow the 
catalase-peroxide reaction. Reaction mixture 
consisted of 2.9 mL of 10 mM H2O2 in 50 μM 
Potassium phosphate buffer (pH 7) and 0.1 mL 
of tissue homogenate. Decrease in the 
absorbance at 240 nm was recorded 
spectrophotometrically for 3 min (UV- 1601, 
Shimadzu). The results were expressed as units 




The LPO content in the brain homogenate was 
determined by the spectrophotometric method as 
described previously [19]. Tissue homogenate 
(0.2 mL) was added to a mixture of 0.2 mL of 8.1 
% SDS, 1.5 mL of 20 % acetic acid solution 
adjusted to pH 3.5 with NaOH, and 1.5 mL of 0.8 
% aqueous solution of thiobarbituric acid (TBA). 
The final mixture volume was adjusted to 4.0 mL 
with distilled water, and then heated at 95 °C for 
60 min in a water bath. After cooling, 1 mL of 
distilled water and 5.0 mL of the mixture of n-
butanol and pyridine (15:1, v/v) were added to 
the final reaction mixture and shaken vigorously. 
After centrifugation at 4000 rpm for 10 min, the 
absorbance of organic layer was measured 
spectrophotometrically (UV- 1601, Shimadzu) at 
532 nm. LPO was expressed in terms of 
nanomoles of malondialdehyde (MDA) per mg of 
protein. 
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All data are presented as mean ± SEM. 
Statistical analysis was performed with SAS 
statistical software (SAS Institute, Cray, NC, 
USA) using one-way analysis of variance, 
followed by Dunnett's tests. P < 0.05 was 




Effect of CCY extract on MPTP-induced 
locomotor impairment in mice 
 
As shown in Fig 1, MPTP toxicity significantly (p 
< 0.001) impaired locomotor activity son day 5 
(9.85 ± 1.35) and day 20 (27.64 ± 0.94). 
Administration of CCY extract at various doses 
(100, 200 and 300 mg/kg) did not influence the 
MPTP-induced locomotor deficits on day 5. 
However, on day 20 CCY extract (100, 200 and 
300 mg/kg) significantly attenuated the 
decreased locomotor activity in a dose-
dependent fashion (37.21 ± 0.92; p < 0.05, 40.26 
± 1.13; p < 0.05 and 47.54 ± 1.19; p < 0.001 at 
100, 200 and 300 mg/kg, respectively). 
 
Effect of CCY extract on MPTP-induced 
passive avoidance in mice 
 
As shown in Fig 2, no significant differences 
were observed in latency time in any group in the 
absence the aversive foot-shock stimulus 
(acquisition trial). The latency time was 
significantly increased in retention trial (298 ± 
3.68 s) compared to acquisition trial (18.26 ±1.97 
s) in control trained group. In addition, the 
latency to enter the dark compartment was 
significantly decreased 24 h after foot shock in 
MPTP-treated mice compared with control mice 
(control mice: 298.5 ± 1.5 s; MPTP-treated mice: 
207.28±4.12 s, p < 0.001 vs. control mice). 
However, CCY extract treatment at indicated 
doses (100, 200 and 300 mg/kg) significantly 
attenuated the decreased latency time (238.63 ± 
7.78 s; p < 0.05, 248.94 ± 8.89 s; p < 0.05 and 
269.26 ± 8.21 s; p < 0.01) at 100, 200 and 300 
mg/kg, respectively. 
 
Effect of CCY extract on open field test in 
MPTP-exposed mice 
 
MPTP-treated mice showed a significant (p < 
0.001) impairment in all the four parameters 
tested when compared with normal control group 
(Figure 3). However, CCY significantly 
attenuated the MPTP-induced reduction in line 
crossing number, rearing number and grooming 
behavior in mice. The effects observed at 
indicated doses were dose-dependent and the 
highest effect was observed at 300 mg/kg dose 
(p < 0.001). Furthermore, the increased 
immobility time in MPTP-induced mice group was 
significantly lowered (p < 0.001 at 300 mg/kg) in 
CCY treated groups dose-dependently. 
 
Figure 1: Effect of CCY extract on the MPTP-induced locomotor impairment in mice. Rotarod performance in 
different experimental groups on day 5 and day 20 was shown; #p < 0.001 compared with their respective 
untreated groups. NS: Not significant; *p<0.05 and ***p<0.001 compared with MPTP-induced group. Data 
expressed as mean ± SEM (n = 5) using one-way ANOVA followed by Dunnett's test; MPTP: 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine; CCY: Cuminum cyminum extract 
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Figure 2: Effect of CCY extract on the MPTP-induced cognitive impairment in mice. Latency times (s) in 
acquisition (trial 1) was carried on day 20 and retention (Trial 2) was carried 24 h after trial 1 (Day 21). □: 
Acquisition, ■: Retention. #p < 0.001 compared with untreated group. NS: Not significant. *p<0.05 and **p<0.01 
compared with MPTP-induced group. Data expressed as mean ± S.E.M. (n=5) using one-way ANOVA followed 
by Dunnett's tests using Graph Pad Prism v5.01 software. MPTP: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 
CCY: Cuminum cyminum extract 
 
 
Figure 3: Effect of CCY extract on the MPTP-induced open-field performance in mice. A: Line crossing, B: 
Rearing, C: Grooming and D: immobility time was measured in different experimental groups. #p < 0.001 
compared with untreated group; *p < 0.05, **p < 0.01 and ***p < 0.001compared with MPTP-induced group. Data 
are expressed as mean ± SEM (n = 5) using one-way ANOVA followed by Dunnett's test. MPTP: 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine; CCY: Cuminum cyminum extract 
 
Effect of CCY extract on antioxidant enzymes 
in MPTP-treated mouse brain tissue 
 
As shown in Fig. 4, significant decrease in the 
activities of SOD and CAT was observed in 
MPTP-treated group (p < 0.001) when compared 
with their respective control groups (Fig 4A and 
B). Furthermore, LPO levels were significantly (p 
< 0.001) increased in MPTP-induced group (Fig 
4C). However, CCY treated groups (100, 200 
and 300 mg/kg) dose dependently attenuated 
these changes. Although 100 mg/kg dose of 
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CCY did not show significant effect in altering the 
SOD and LPO activity, the effects were dose-
dependent. The highest effect was observed at 
300 mg/kg dose (p < 0.001). 
 
 
Figure 4: Effect of CCY extract on the anti-oxidant 
enzyme levels in MPTP-induced mice. The antioxidant 
enzymes levels in different experimental groups were 
shown. A: Superoxide dismutase (SOD), B: catalase 
(CAT) and C: Lipid peroxides (LPO); #p < 0.001 
compared with untreated group. *p < 0.05, **p < 0.01 
and ***p < 0.001compared with MPTP-induced group. 
Data expressed as mean ± S.E.M. (n=5) using one-
way ANOVA followed by Dunnett's tests. MPTP: 1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine; CCY: 




In the present study, CCY extract attenuated the 
cognitive and behavioral impairments in MPTP-
treated mouse model of PD. The enhanced 
cognitive and behavioral function exhibited by 
CCY extract treatment was strongly supported by 
the reduced brain oxidative stress in MPTP-
induced mice. It is well documented that MPTP-
injected mice led to a decreased latency to fall on 
an accelerating rota rod apparatus, reflecting 
diminished balance and loss of muscular 
coordination [20]. Locomotor dysfunction 
including tremors, rigidity and bradykinesia are 
various kinds of clinical symptoms of PD [21]. 
Since the behavioral effects are intertwined with 
the degree of neuronal dysfunction, its 
assessment is a more powerful endpoint in 
evaluating neuroprotection. 
 
In the present study, results from behavioral 
assessment through rota rod test suggest that 
long term treatment of CCY extract improved 
muscular activity and locomotion. It is well known 
that MPTP-induction to non-human primates and 
mice develop cognitive deficits [12,13]. 
Therefore, testing the behavioral function 
provides a sensitive evaluation of the CCY’s 
ability to provide neuroprotection. In agreement, 
MPTP-induced mice significantly altered the 
cognitive performance with poor performance in 
passive avoidance and open field tasks. Mice 
administered 300 mg/kg CCY extract showed a 
significant improvement compared with lower 
doses (100 and 200 mg/kg).  
 
MPTP damage mitochondria, proteins and lipids 
thereby altering the anti-oxidant enzyme status in 
the brain [22]. Therefore, estimating the 
antioxidant enzyme status in brain might be 
beneficial in understanding the degree of MPTP-
intoxication in animal models. Furthermore, 
reports also revealed that antioxidant 
supplementation attenuated the reduced 
dopamine (DA) level and behavioral deficits in 
Parkinsonian mice [20,23,24]. In the present 
study, the oxidative stress in MPTP-induced 
Parkinsonian mice was measured by determining 
the activity of SOD, CAT and LPO levels in the 
mouse brain tissues.  CCY extract treatment 
ameliorated the MPTP-induced reduction in the 
activities of antioxidant enzymes and resulted in 
reduced levels of oxidative stress. CCY extract 
effectively improved antioxidant enzyme activities 
in MPTP treated animals especially at the dose 
of 300 mg/kg. The anti-oxidant effects observed 
in this study were in agreement with our earlier 
reported works, that C. cyminum extract has 
ability to scavenge free radicals [6,10]. 
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The major active constituents of CCY extract are 
cuminol, cymine, cuminaldehyde, limonene, 
eugenol, α & β-pinenes, terpenes and glucosides 
[25]. Some of these compounds are known to 
possess antioxidant activities [26-28]. These 
compounds might act individually or in a 





The findings of this study indicate that CCY 
extract attenuates MPTP-induced cognitive and 
behavioural impairments in mouse model of PD. 
Further, MPTP-induced alteration in anti-
oxidative enzyme levels (SOD, CAT and LPO) 
was reversed in PD mouse brain tissues treated 
with CCY. Regulation of antioxidant defense 
mechanisms by CCY may partly be responsible 
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